Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt and Palatin sign LeuTech agreement:

This article was originally published in Clinica

Executive Summary

Palatin's first commercial product, LeuTech, will be licensed to Mallinckrodt. Saint Louis, Missouri-based Mallinckrodt will pay Princeton, New Jersey-based Palatin a $500,000 licensing fee and buy 700,000 Palatin shares for a total of $13 million. LeuTech is a radiolabelled monoclonal antibody for diagnosing infections. It is injected into a vein and a gamma camera locates the agglomeration of white cells at the infection site. The initial indication is for equivocal cases of appendicitis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel